ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 145 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2021. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $139 | -12.6% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $159 | -74.5% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $623 | -37.7% | 100 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 100 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 100 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | -33.3% | 100 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $3,000 | -25.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $4,000 | -20.0% | 100 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $5,000 | -16.7% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $6,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $6,000 | +50.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $4,000 | -20.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $5,000 | -28.6% | 100 | 0.0% | 0.00% | -33.3% |
| Q1 2018 | $7,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
| Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
| Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
| RA Capital Management | 704,701 | $24,883,000 | 3.05% |
| Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
| BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
| Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
| Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
| Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
| FT Options LLC | 22,834 | $806,000 | 1.06% |